OraSure Technologies CEO Carrie Eglinton Manner said in her presentation that the firm's recent $25 million acquisition of ...

Highlights from the third day included information about Quanterix's new Simoa One platform, expected to launch at the end of ...

The Dublin-based firm said that it will use the money for development for its rapid test to aid the diagnosis and treatment of sepsis.

The proteomic blood test could be a noninvasive tool used to improve detection of the condition, which currently takes an average of 7.5 years to diagnose.

The firm will use its blood-based tests to explore connections between Alzheimer's disease and neuronal α-synuclein conditions including Parkinson's disease.

Rounding out the other four largest financing rounds in 2024 are proteomics company Alamar Biosciences' $128 million Series C ...

Sapient will be an Alamar certified service provider for Alamar's NULISAseq Inflammation panel and its NULISAseq CNS Disease panel.

NEW YORK — Owlstone Medical, a UK-based developer of breath-based diagnostics, said on Wednesday that it has closed a $27 million Series E financing round.

The firm said preliminary core Q4 2024 revenues are expected to be flat, exceeding prior expectations, while its China business has stabilized and will recover.

SAN FRANCISCO — QuidelOrtho CEO Brian Blaser noted in his presentation that in 2024 the company made changes to position the firm for near- and long-term growth, including flattening the ...

The test detects HIV-1/2 antibodies in finger prick samples and is intended for use by healthcare professionals in any healthcare setting.